Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancers

  • Ziegler, David (Primary Chief Investigator (PCI))
  • Strong, Robyn, (Project Manager)

Project: Research

Project Description

The primary objective of this study is to evaluate the objective response rate (ORR) to nivolumab in paediatric patients with refractory or recurrent hypermutated malignancies, including patients with replication repair deficiencies (RRD), such as constitutional mismatch repair deficiency (CMMRD).
Short titleOZM-075
StatusActive
Effective start/end date1/10/1930/09/22

Funding

  • Cure Brain Cancer Foundation: AUD89,796.00